Logo for Atossa Therapeutics Inc

Atossa Therapeutics Investor Relations Material

Latest events

Logo for Atossa Therapeutics Inc

Q2 2023

Atossa Therapeutics
Logo for Atossa Therapeutics

Q1 2024

13 May, 2024
Logo for Atossa Therapeutics

Q4 2023

1 Apr, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Atossa Therapeutics Inc

Access all reports
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines that address significant unmet medical needs in oncology, with a specific focus on breast cancer. The company's lead program is Endoxifen, an active metabolite of tamoxifen, currently in clinical trials for the treatment and prevention of breast cancer. Additionally, Atossa is working on AT-H201 for lung injury caused by cancer treatment and is involved in developing immunotherapy/chimeric antigen receptor therapy programs. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.